Effectiveness of Brentuximab vedotin before and after allogeneic stem cell transplantation in the management of transformed mycosis fungoides.

Effectiveness of Brentuximab vedotin before and after allogeneic stem cell transplantation in the management of transformed mycosis fungoides.
Br J Dermatol. 2019 Dec 19;:
Authors: André R, Ram-Wolff C, Battistella M, de Latour RP, Petit A, Bouaziz JD, Brice P, Bagot M, de Masson A
Abstract
Brentuximab vedotin (BV) is an antibody-drug conjugate, composed of a humanized anti-CD30 IgG1 and of the anti-mitotic monomethyl auristatine E1 . The interest of BV in the management of CD30-positive mycosis fungoides (MF) and primary cutaneous anaplastic large cell lymphoma has recently been demonstrated compared to methotrexate or bexarotene.
PMID: 31854457 [PubMed - as supplied by publisher]

Source: The British Journal of Dermatology - December 18, 2019 Category: Dermatology Authors: André R, Ram-Wolff C, Battistella M, de Latour RP, Petit A, Bouaziz JD, Brice P, Bagot M, de Masson A Tags: Br J Dermatol Source Type: research